We mainly focus our research effort on
identifying specific cancer diagnostic or prognostic biomarkers to improve the
management of cancer. In collaboration with our academic and industrial partners,
we have several projects ongoing.
Profiling the genetic and epigenetic core signatures for gastrointestinal
cancers at different stages
each cancer genome, among the many diversified genetic mutations, some are
driver gene mutations, and the remaining large amount are passenger mutations.
Next generation sequencing (NGS) makes it feasible to study cancer genome
aim of this project is to profile the genetic and epigenetic alterations of
cancer cells, and to provide insight into cancer initiation, progression, early
diagnosis, and prognosis.
Characterization and validation of key molecular changes identified in
In last decade, a number of molecules, including proteins, miRNAs, mRNAs, and
specific metabolites have been suggested to be biomarkers of different types of
cancers. Our research seeks to further
characterize and validate these molecules, and to evaluate the feasibility of
applying these molecules to our diagnostic development.